Background: In the Democratic Republic of Congo, the use of Prevention of Transmission of Human Immunodeficiency Virus infection from mother to child is still very low. Objective: The objective of this study was to estimate the prevalence of infants born from HIV-positive mother in different centers in Kinshasa. Methods: This study is a retrospective cohort of at least 2 years on the records of mother-child couple followed in 8 centers of Kinshasa. Based on a sample survey form with specific criteria, some files were selected. Results: The record keeping of all centers was estimated at 70% on average; the most represented age group was from 26 to 35 years with 102 women (54%) out of 190. Forty-five percent (45%) of pregnant women started pre-natal consultation (CPN) in the 2nd trimester of pregnancy. All mothers had been diagnosed with 3 Rapid Diagnostic Tests (RDT). The majority of women were under: AZT + 3TC + NVP and CTX and 139 (73%) women were diagnosed at stage 1 of HIV infection according to WHO's standard. One hundred new born were male. Seventy-eight newborns weighed between 2.01 and 3.00 kg at birth. Ninety seven percent of newborns were treated at birth. Ninety-one children who were on Nevirapine syrup; six of them were not put on treatment. Ninety five percent of newborns were diagnosed HIV-negative 9 months after birth by PCR; 2% of children were undiagnosed as a result of refusal and 3% of children had undetermined serology. This gives a mother-to-child transmission rate of 2% at 9 months of birth for the centers of Kinshasa. Conclusion: Despite the insufficient coverage of the
Background: The Early Warning Indicators (EWI) of Human Immunodeficiency Virus (HIV) Drug Resistance measure factors found at the site level and known to be associated with the proper functioning of the program and the prevention of the emergence of R-ARV. The fact strengthening certain aspects of implementation of the program at the sites can help minimize the occurring of HIV Drug Resistance that can be prevented to improve the long-term effectiveness and sustainability of the treatment. Objective: The objective of this study was to assess the quality of the prevention of resistance of HIV Drug compared to EWI set by the World Health Organization (WHO) in the different Ambulatory Treatment Centers (ACT) in the city of Kinshasa. Methods: The present work was a retrospective survey conducted in 2015 in 7 ACTs in the 4 districts of Kinshasa in order to evaluate the EWI. Results: Seven (7) ATCs and 157 patient records were selected based on different inclusion criteria. The maintenance of first-line Antiretroviral Treatment (ART) at 12 months and the consistent delivery of ARVs were the two EWI that were respected, evaluation at 100%, for 6 ACTs. Conclusion: The caregivers and HIV-infected patients should be trained on the EWI and their monitoring to prevent the occurrence of treatment failures and that of HIV drug resistance in Kinshasa.
Background: Viral hepatitis represents a major public health burden with more than 375 million people with chronic hepatitis B infection and 130 to 150 million with hepatitis C for 2016. Sub-Saharan Africa has the heaviest burden of the epidemic. Objective: The objective of this review is to present the characteristics of hepatitis B and C infections (HBV and HCV), present the synthesis and estimate its magnitude in the Democratic Republic of Congo for the last 20 years. Methods: This work consisted in cataloging the various published articles and abstracts presented in scientific conferences having as subject of interest the infection with viral hepatitis B and C in the DRC.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.